143 filings
Page 2 of 8
8-K
6pe n51a9j4h
27 Feb 24
MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
5:23pm
8-K
kq6ninws38
23 Feb 24
MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
4:17pm
424B5
08tnf8m
14 Feb 24
Prospectus supplement for primary offering
5:18pm
8-K
gion2lzby059a vtm
14 Feb 24
Entry into a Material Definitive Agreement
5:15pm
8-K
xi2gz 46gdeak
30 Jan 24
MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds
9:00am
8-K
ebfuu
18 Jan 24
MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024
6:01am
8-K
0p2wsgs
21 Dec 23
MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
7:00am
D
gvln94nom4kv9
29 Nov 23
$4.86 mm in equity / options / securities to be acquired, sold $4.86 mm, 3 investors
4:19pm
8-K
yhvy0xgti0kvvla0tuta
17 Nov 23
MAIA Biotechnology Announces $4 Million Registered Direct Offering
9:09am
424B5
kpq87ejmbonb0g7a0g
17 Nov 23
Prospectus supplement for primary offering
9:06am
8-K
52w7dbmvdaxai1h0wz
16 Nov 23
Entry into a Material Definitive Agreement
5:26pm
8-K
vermp01nfndkpine
15 Nov 23
Termination of a Material Definitive Agreement
8:42am
424B5
hnhwnej 6vig130xu
15 Nov 23
Prospectus supplement for primary offering
8:41am
8-K
13pr6kfb0 iu1
13 Nov 23
Other Events
6:07am
8-K
v8ys0l6 5bod2
7 Nov 23
MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO
8:05am
8-K
d2mu671y2
30 Oct 23
Other Events
5:24pm
8-K
xhzxxxdfkbrnc
28 Sep 23
MAIA Biotechnology Announces Share Repurchase Program
5:12pm
8-K
l3dsu
1 Sep 23
Entry into a Material Definitive Agreement
4:45pm
424B5
witetz gq4v0tb
1 Sep 23
Prospectus supplement for primary offering
4:30pm